...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Open medicine >Effects of budesonide combined with noninvasive ventilation on PCT, sTREM-1, chest lung compliance, humoral immune function and quality of life in patients with AECOPD complicated with type II respiratory failure
【24h】

Effects of budesonide combined with noninvasive ventilation on PCT, sTREM-1, chest lung compliance, humoral immune function and quality of life in patients with AECOPD complicated with type II respiratory failure

机译：布地奈德联合无创通气对AECOPD合并II型呼吸衰竭患者PCT，sTREM-1，胸肺顺应性，体液免疫功能和生活质量的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective Our objective is to explore the effects of budesonide combined with noninvasive ventilation on procalcitonin (PCT), soluble myeloid cell triggering receptor-1 (sTREM-1), thoracic and lung compliance, humoral immune function, and quality of life in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) complicated with type II respiratory failure. Methods There were 82 patients with AECOPD complicated with type II respiratory failure admitted into our hospital between March, 2016-September, 2017. They were selected and randomly divided into observation group (n=41) and control group (n=41). The patients in the control group received noninvasive mechanical ventilation and the patients in the observation group received budesonide based on the control group. The treatment courses were both 10 days. Results The total effective rate in the observation group (90.25%) was higher than the control group (65.85%) (P0.05). The scores of cough, expectoration, and dyspnea were decreased after treatment (Observation group: t=18.7498, 23.2195, 26.0043, control group: t=19.9456, 11.6261, 14.2881, P0.05); the scores of cough, expectoration, and dyspnea in the observation group were lower than the control group after treatment (t=11.6205, 17.4139, 11.6484, P0.05). PaO2 was increased and PaCO2 was decreased in both groups after treatment (Observation group: t=24.1385, 20.7360, control group: t=11.6606, 9.2268, P0.05); PaO2 was higher and PaCO2 was lower in the observation group than the control group after treatment (t=10.3209, 12.0115, P0.05). Serum PCT and sTREM-1 in both groups were decreased after treatment (Observation group: t=16.2174, 12.6698, control group: t=7.2283, 6.1634, P0.05); serum PCT and sTREM-1 in the observation group were lower than the control group after treatment (t=10.1017, 7.8227, P0.05). The thoracic and lung compliance in both groups were increased after treatment (Observation group: t=30.5359, 17.8471, control group: t=21.2426, 13.0007, P0.05); the thoracic and lung compliance in the observation group were higher than the control group after treatment (t=10.8079, 5.9464, P0.05). IgA and IgG in both groups were increased after treatment (Observation group: t=9.5794, 25.3274, control group: t=5.5000, 4.7943, P0.05), however IgM was not statistically different after treatment (Observation group: t=0.7845, control group: t=0.1767, P0.05); IgA and IgG in the observation group were higher than the control group (t=4.9190, 4.7943, P0.05), however IgM was not statistically different between two groups after treatment (t=0.6168, P0.05). COPD assessment test (CAT) scores were decreased in both groups after treatment (Observation group: t=20.6781, control group: t=9.0235, P0.05); CAT score in the observation group was lower than the control group after treatment (t=12.9515, P0.05). Forced expiratory volume in one second (FEV1%) and forced expiratory volume in one second/ forced expiratory volume in one second (FEV1/FVC) were increased in both groups after treatment (Observation group: t=15.3684, 15.9404, control group: t=10.6640, 12.8979, P0.05); FEV1% and FEV1/FVC in the observation group were higher than the control group (t=6.9528, 7.3527,P0.05). The rates of complication were not statistically different between two groups (P0.05). Conclusion Budesonide combined with noninvasive mechanical ventilation has good curative effects in treating AECOPE patients complicated with type II respiratory failure. It can decrease serum PCT and sTREM-1, increase thoracic lung compliance, and improve the humoral immune function and life quality.
机译：目的我们的目的是探讨布地奈德联合无创通气对急性降钙素（PCT），可溶性髓样细胞触发受体1（sTREM-1），胸肺顺应性，体液免疫功能以及生活质量的影响慢性阻塞性肺疾病（AECOPD）恶化并发II型呼吸衰竭。方法选择2016年3月至2017年9月在我院收治的AECOPD合并Ⅱ型呼吸衰竭患者82例，随机分为观察组（n = 41）和对照组（n = 41）。对照组患者接受无创机械通气，观察组患者接受布地奈德治疗。治疗过程均为10天。结果观察组总有效率（90.25％）高于对照组（65.85％）（P <0.05）。治疗后咳嗽，咳嗽和呼吸困难评分降低（观察组：t = 18.7498、23.2195、26.0043，对照组：t = 19.9456、11.6126、14.2881，P <0.05）;治疗后观察组咳嗽，咳嗽，呼吸困难评分均低于对照组（t = 11.6205、17.4139、11.6484，P <0.05）。治疗后两组PaO2升高，PaCO2降低（观察组：t = 24.1385，20.7360，对照组：t = 11.6606，9.2268，P <0.05）;观察组治疗后PaO2升高，PaCO2降低（t = 10.3209，12.0115，P <0.05）。治疗后两组血清PCT和sTREM-1均降低（观察组：t = 16.2174、12.6698，对照组：t = 7.2283、6.1634，P <0.05）;观察组治疗后血清PCT和sTREM-1均低于对照组（t = 10.1017，7.8227，P <0.05）。治疗后两组胸，肺顺应性均升高（观察组：t = 30.5359，17.8471，对照组：t = 21.2426，13.0007，P <0.05）。治疗后观察组胸，肺顺应性高于对照组（t = 10.8079，5.9464，P <0.05）。两组治疗后IgA和IgG均升高（观察组：t = 9.5794，25.3274，对照组：t = 5.5000，4.7943，P <0.05），但治疗后IgM差异无统计学意义（观察组：t = 0.7845，对照组：t = 0.1767，P> 0.05）;观察组的IgA和IgG均高于对照组（t = 4.9190，4.7943，P <0.05），但两组治疗后的IgM无统计学差异（t = 0.6168，P> 0.05）。两组治疗后COPD评估测试（CAT）评分均降低（观察组：t = 20.6781，对照组：t = 9.0235，P <0.05）;治疗后观察组的CAT评分低于对照组（t = 12.9515，P <0.05）。两组治疗后两组的一秒用力呼气量（FEV1％）和一秒用力呼气量/一秒用力呼气量（FEV1 / FVC）均增加（观察组：t = 15.3684，15.9404，对照组：t = 10.6640、12.8979，P <0.05）;观察组的FEV1％和FEV1 / FVC高于对照组（t = 6.9528，7.3527，P <0.05）。两组的并发症发生率无统计学差异（P> 0.05）。结论布地奈德联合无创机械通气治疗AECOPE合并II型呼吸衰竭的疗效较好。它可以降低血清PCT和sTREM-1，增加胸肺顺应性，并改善体液免疫功能和生活质量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号